se of Sumac in treatment of hyperlipidemia
Not Applicable
- Conditions
- Hyperlipidemia.Hyperlipidaemia, unspecified
- Registration Number
- IRCT2014030716876N1
- Lead Sponsor
- Vice chancellor of Research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
• Age: 20-65 years old.
• Serum triglyceride more than 150mg/dl and /or total cholesterol equal or more than 240mg/dl.
Exclusion criteria:
• Serum triglyceride more than 500 mg/dl.
• Serum LDL-cholesterol at level which need drug treatment according to the patient risk categories (NCEPATP III).
• Diabetes mellitus.
• Hypo or hyperthyroidism.
• Any systemic illnesses e.g. liver cirrhosis, acute or chronic renal failure, heart failure.
• Use of drugs: OCPs, lipid lowering agents, thiazides.
• Pregnancy.
• Alcoholism.
• History of allergic reaction to Sumac.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum total cholesterol level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum triglyceride level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum HDL-cholesterol level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum LDL-cholesterol level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.
- Secondary Outcome Measures
Name Time Method Serum ALT level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum AST level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Fasting Blood Sugar (FBS). Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum creatinin level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.;Serum alkaline phosphatase level. Timepoint: 6 weeks. Method of measurement: Biochemical analysis.